Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, Capozzi ME, van der Velden WJ, Stutsman C, Cardona GR, Urva S, Emmerson PJ, Holst JJ, DAlessio DA, Coghlan MP, Rosenkilde MM, Campbell JE, Sloop KW
Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO
Ana har bu kalplara boaltlr ve titreim sistemiyle sklatrlr
The patient has achieved at least a 5% reduction in baseline body weight or has maintained this 5% weight loss
Ostrovsky O, et al
It is the first and so far only dual receptor agonist, activating both the GIP receptor (glucose-dependent insulinotropic polypeptide) and the GLP-1 receptor (glucagon-like peptide-1) at the same time